Login to Your Account



Amyloid Red Herring?

Dimebon Bust 'No Surprise': Back to Drawing Board in AD

By Randy Osborne


Monday, March 15, 2010
Medivation Inc.'s stock-jolting Phase III blow-up with Dimebon (latrepirdine) for Alzheimer's disease imperiled the firm's deal with Pfizer Inc., triggered shareholder class-action lawsuits and upped the ante for already hard-pressed developers of AD therapies across the board.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription